to the Boehringer Ingelheim Pharmaceutical Inc (BIPI) and Lilly USA, LLC (Lilly)
Alliance on-line application and grant management portal.
On January 11,
2011 BIPI and Lilly announced a global agreement to jointly develop and
commercialize a portfolio of diabetes compounds. We are committed to supporting
education that fosters innovative, high quality, independent medical education
for healthcare professionals and patients that narrows unmet medical needs,
maintains clinical excellence, and measurably improves health outcomes in areas
of interest to the BIPI and Lilly Diabetes Alliance.
By agreement between
BIPI and Lilly, grant requests will be processed through the BIPI on-line grant
system but the application request will be reviewed by both companies. The
following steps are required in order to process your grant request through our
on-line grant management portal:Medical Education Grants
A BIPI/Lilly medical education grant is designed to support independent
medical education for healthcare providers and patients that may translate to
better management of disease and improvement in patient safety and population
health.Please see below for submission timelines:
- Grant applications with total program costs/expenses of $25,000.00 or
less, must be submitted no less than 60 days prior to the program start date.
- Grant applications with total program costs/expenses greater than
$25,000.00, must be submitted no less than 90 days prior to the program start
New and Returning Visitors to BIPI/Lilly Medical
To begin a new application, return to a saved application, or
track the status of an application already submitted login at https://bipisupport.envisionpharma.com/vt_bi/.
If this is the first time you are visiting the site, you must register as a New
User. An application ID beginning with "ME", will be assigned once you submit
- Discuss the mechanisms of action and clinical data
related to incretin based therapies or insulin independent treatment
- Outline the morbidity, mortality and cost burdens that
result from inadequate management of T2DM in diverse populations (race,
ethnicity, gender and age etc).
- Describe the role of individualized, multifaceted
approaches to improving outcomes in relation to diabetes-related health
issues including microvascular and/or macrovascular complications.
- Improve awareness of the importance of early
recognition, clinical detection, and diagnosis of renal compromise and
appropriate glycemic management in patients with T2DM.
- Discuss clinical strategies to incorporate therapeutic
classes and agents with insulin independent mechanisms of action into
practice recommendations for the care of patients with T2DM.
- Discuss new models of care in the management of T2DM
which may assist providers in delivering improved patient care and educate
patients on the importance of self-management of their disease.
Responding to a Request for Educational Grant Application
Throughout the year, the Medical Grants department may announce a
Request for Educational Grant Application (REGA). The intent of this
announcement is to notify experienced and accredited Continuing Medical
Education (CME) providers and accredited Continuing Education (CE) providers
that BIPI/Lilly is interested in receiving applications for educational grants
for support consideration.
Grant applications in response to BIPI/Lilly
Alliance REGAs need to be submitted online at https://bipisupport.envisionpharma.com/vt_bi.
While REGAs may specify timing of requested responses, BIPI and Lilly will
continue to review all grant requests which are received.
To contact the
BIPI/Lilly Alliance Medical Grants Department, please call (800) 295-0717. (8:00
a.m. - 5:00 p.m. EST, Monday – Friday)